Cincinnati and Dayton, Ohio

Melanoma Clinical Trials- Recruiting

Phase
NCT00454701
Assessment and Tracking of Long-term Alefacept Safety		 Phase IV
NCT00297895
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)		 Phase III
NCT01274338
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery		 Phase III
NCT00297895
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)		 Phase III
NCT01274338
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery		 Phase III
NCT01274338
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery		 Phase III
NCT01120275
RO4929097 in Treating Patients With Stage IV Melanoma		 Phase II
NCT01127451
Study of ONTAK in Patients With Stage IIIC and Stage IV Melanoma		 Phase II
NCT01248936
A Study of RO5185426 in Patients With Metastatic Melanoma		 Phase II
NCT01136967
An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma		 Phase II
NCT01120275
RO4929097 in Treating Patients With Stage IV Melanoma		 Phase II
NCT00976573
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma		 Phase II
NCT01120275
RO4929097 in Treating Patients With Stage IV Melanoma		 Phase II
NCT00976573
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma		 Phase II
NCT01120275
RO4929097 in Treating Patients With Stage IV Melanoma		 Phase II
NCT00730639
A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies		 Phase I
NCT00931931
HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors		 Phase I
NCT00897442
Collecting Tumor Samples From Patients With Gynecological Tumors
Updated from clinicaltrials.gov on 8/24/2011

Comments are closed.